Time limits apply in New Jersey. Find out if you still qualify.
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Verified against court and regulatory records · No upfront fees · Your information is never sold
Statute of limitations — New Jersey
The New Jersey Products Liability Act (N.J.S.A. 2A:58C) imposes a 2-year statute of limitations for product liability claims. The discovery rule applies — the clock starts when the plaintiff knew or reasonably should have known about the hearing injury and its connection to Tepezza treatment. New Jersey has a 10-year statute of repose for product liability, but since Tepezza was first sold in 2020, this deadline is not yet applicable.
2 years from discovery of Tepezza-related hearing injury
Filing venue
Where to File in New Jersey
Federal Tepezza cases from New Jersey are transferred to the MDL in the Northern District of Illinois (MDL No. 3079). New Jersey state court claims may proceed in Bergen, Essex, or Middlesex County Superior Courts. New Jersey is one of the most experienced pharmaceutical litigation jurisdictions in the country, having hosted the Elmiron MDL (2973) and numerous other drug injury proceedings. The state applies a modified Daubert standard for expert testimony under N.J.R.E. 702.
New Jersey data
Exposure in New Jersey
New Jersey population — state ranks among the highest per capita for endocrinology specialists and thyroid disease treatment centers
9.3 million
Source: U.S. Census Bureau 2024
Primary type of hearing loss associated with Tepezza — caused by damage to cochlear hair cells deprived of IGF-1R survival signaling that the drug blocks
Sensorineural
Source: PMC / National Library of Medicine
Date Amgen completed $27.8 billion acquisition of Horizon Therapeutics, assuming all Tepezza product liabilities
December 2023
Source: SEC filings
Keep reading